Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3012% above fair value
$9.37+0.06 (+0.64%)
Close on Nov 13, 2026Market cap $799.39MP/E –Yield –
Monte Rosa Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Monte Rosa Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -214.5%. For fiscal 2025 it was -43.8%, against -107.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -43.8% | +63.4 |
| FY2024 | Dec 31, 2024 | -107.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3.6% | +254.7 |
| Q2 FY2026 | Jun 30, 2026 | -547.8% | −480.8 |
| Q1 FY2026 | Mar 31, 2026 | -1188.5% | −1240.3 |
| Q4 FY2025 | Dec 31, 2025 | -1787.7% | −1809.1 |
| Q3 FY2025 | Sep 30, 2025 | -258.3% | +29.6 |
| Q2 FY2025 | Jun 30, 2025 | -67.1% | +628.2 |
| Q1 FY2025 | Mar 31, 2025 | 51.9% | +3336.3 |
| Q4 FY2024 | Dec 31, 2024 | 21.4% | – |
| Q3 FY2024 | Sep 30, 2024 | -287.8% | – |
| Q2 FY2024 | Jun 30, 2024 | -695.3% | – |
| Q1 FY2024 | Mar 31, 2024 | -3284.5% | – |
See a number that looks wrong?